Treatment of Relapsed/Refractory Myeloma (excluding T-cell redirection therapy)
Carfilzomib, Lenalidomide and Dexamethasone (KRD) therapy post autologous stem-cell transplantation (ASCT): real-world data in multiple myeloma patients eligible for second ASCT.
Vilmante Vaitekenaite, MD
Hematologist
Hematology, Oncology and Transfusion Medicine Center, Vilnius University Hospital Santaros Klinikos
Vilnius, Lithuania